Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 21 February 2018

Indication(s)

- Exelon hard capsules / Exelon oral solution:
Symptomatic treatment of mild to moderately severe Alzheimer’s dementia.

Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease.



- Exelon transdermal patch:
Symptomatic treatment of mild to moderately severe Alzheimer’s dementia.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000169
Orphan designation No
Date First Approved 12-05-1998
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Novartis Europharm Limited